ClinicalTrials.gg
RecruitingNCT06877858Updated Oct 19, 2026

MethaLoad Dose-Finding Study

A Phase 1 interventional study of Methadone hydrochloride in Opioid Use Disorder (OUD), sponsored by Ashish P Thakrar, MD MS. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Ashish P Thakrar, MD MS · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.

Planned enrollment
15th of 19
24 · median 68
Started
2025
the only one that year
Phase 1
3 of 19
1 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Ashish P Thakrar, MD MS

Among the 19 studies testing methadone in Opioid-Related Disorders, this one is the 15th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 18th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing methadone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

Methadone is an effective treatment for opioid use disorder (OUD), but starting it has become harder now that most people with OUD use fentanyl. Methadone is usually started at a low dose and increased slowly over several weeks. For people who use fentanyl, these low early doses might not relieve withdrawal and cravings, and many people stop treatment before reaching a dose that works.

This study will test whether starting methadone with a higher first-day dose (a "loading dose") is safe and comfortable for people who use fentanyl. It will also help find the best loading dose to test in future, larger studies.

We will enroll 24 adults with OUD who use fentanyl. Participants will start methadone while staying on an inpatient research unit, where staff will monitor them closely. Each person will get either the usual starting dose or one of four loading doses, assigned by chance. Participants and the staff who rate their symptoms will not know which dose was given. As the study goes on, the research team will use safety results from earlier participants to decide which loading doses later participants receive.

03

Conditions studied

  • Opioid Use Disorder (OUD)

Keywords

  • methadone
  • fentanyl
  • opioid use disorder
  • opioid addiction
  • opiate addiction
  • OUD
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, female, transgender, or non-binary, aged 18 years or older
  2. criteria for opioid use disorder, moderate-severe
  3. Fentanyl positive urine drug test
  4. Able to provide a dated \& written in English prior to the conduct of any study related procedures
  5. Stated willingness to comply with all study procedures and availability for the duration of the study
  6. Ability to take oral medication and be willing to adhere to the dosage regimen
  7. Interest in starting methadone treatment for opioid use disorder at a partner location
  8. Reliable access to a working phone

Exclusion criteria

Exclusion criteria:

  1. or allergy to methadone that is previously documented
  2. Pregnancy or actively lactating (with urine pregnancy test performed on screening and repeated on admission to the unit prior to randomization)
  3. Taking medications for opioid use disorder, per self-report or per urine drug testing detection of buprenorphine or methadone
  4. At risk of benzodiazepine or alcohol withdrawal as defined by: prior benzodiazepine or alcohol withdrawal in the past 3 months, current daily use of benzodiazepines or alcohol, or criteria for hypnotic-sedative or alcohol use disorder
  5. At risk of severe medetomidine withdrawal based on: serum or urine testing for medetomidine (if available), prior withdrawal syndrome requiring intensive care unit admission within past 6 months, and/or severe nausea/vomiting during first 4 hours of withdrawal, at the discretion of the study physicians
  6. At risk for methadone-induced -prolongation: prolonged QTc on screening or admission (greater than 450ms in men, greater than 460ms in women), history of QT prolongation, previously documented long QT syndrome, history of ventricular arrhythmia (e.g., torsades de pointes), history of cardiac hypertrophy, history of cardiac conduction abnormalities, taking medications that affect cardiac conduction (at study physician discretion; including but not limited to: amiodarone, flecainide, sotalol, azithromycin, ciprofloxacin, levofloxacin, citalopram, escitalopram, hydroxychloroquine, chlorpromazine, haloperidol, donepezil, ibogaine, cilostazol), serum potassium concentration less than 3.5 mg/dL, or serum magnesium concentration less than 1.7 mg/dL.
  7. Significant hepatic dysfunction, defined as: and/or ALT 3x , or total 1.5x upper limit of normal
  8. Significant renal dysfunction, defined as: less than or equal to 60 mL/min
  9. Chronic hypotension (\<90/50 mmHg) or episodic symptomatic hypotension, defined as a history of active or recurrent orthostatic hypotension or syncope
  10. Significant pulmonary disease, defined as: baseline SpO2 \<95% on screening or admission, requiring oxygen at home (chronically or at bedtime), or with modified MRC Dyspnea Scale greater than 2 ("I stop for breath after walking about one city block")
  11. Suspected gastrointestinal obstruction, per medical history
  12. Active, chronic use of the -inducers or -inhibitors rifampin, phenytoin, St John's wort, phenobarbital, carbamazepine, voriconazole, efavirenz, nelfinavir, nevirapine, ritonavir, and lopinavir/ritonavir, abacavir, or amprenavir
  13. Pending legal action that could prohibit participation and/or compliance in study procedures
  14. Presence of any other psychiatric and/or medical disorder that, in the opinion of the PI, will interfere with completion of the study or place the patient at heightened risk through participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Treatment as usual (TAU)

    Day 1: 40mg oral methadone Day 2: 40mg oral methadone

    Drug: Methadone hydrochloride

  • Experimental
    Loading Dose

    Day 1: loading dose (60mg, 80mg, 100mg, or 120mg oral methadone) Day 2: 50% of the loading dose (30mg, 40mg, 50, or 60mg oral methadone)

    Drug: Methadone hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) rate

    The primary objective of the study is to identify a methadone loading dose approach appropriate for future study as an alternative initiation strategy for individuals with OUD using fentanyl or other high-potency synthetic opioids. The loading dose appropriate for future study will be identified as the highest loading dose with a dose-limiting toxicity (DLT) rate less than 10%. DLT definition: the proportion of individuals in each loading dose arm who meet any one of four safety outcomes within 24 hours of methadone loading dose administration: (1) Richmond Agitation-Sedation Scale (RASS) less than -1, (2) respiratory rate (RR) less than 8 breaths per minute, (3) peripheral oxygen saturation (SpO2) less than 92%, or (4) corrected QT interval (QTc) greater than 500ms.

    Time frame: 24 hours

Secondary outcomes

  1. Opioid withdrawal severity

    Peak and time-weighted mean subjective opioid withdrawal (using the Subjective Opioid Withdrawal Scale, SOWS) and the Clinical Opiate Withdrawal Scale (COWS) over 24 hours after initial methadone dose

    Time frame: 24 hours

  2. Opioid craving

    Peak and time-weighted mean opioid craving, using a visual analogue scale (VAS) assessment (1-100) over 24 hours after initial methadone dose

    Time frame: 24 hours after initial methadone dose

  3. Peak plasma methadone concentration

    Peak plasma methadone concentration after initial loading dose (Day 1) and after first maintenance dose (Day 2)

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
  • Penn Center for Studies of Addiction (CSA)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 27 months is close to that.

Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Mar 2027 → Dec 2027 and completion Jul 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Dec 31, 2027was Mar 2027
CompletionEst.
Jan 2028was Jul 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Dec 31, 2027
Oct 19, 2026
Study completion
Jul 2027→Jan 2028
Oct 19, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Interest in starting methadone treatment for opioid use disorder at one of three locations: Merakey Parkside at 5000 Parkside, Merakey 5429 Germantown Avenue, or Merakey 1745 North 4th StreetNow Interest in starting methadone treatment for opioid use disorder at a partner location
Oct 19, 2026
Sponsor
University of Pennsylvania→Ashish P Thakrar, MD MS
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Mar 2027→Dec 31, 2027
    Study completion Jul 2027→Jan 2028
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Interest in starting methadone treatment for opioid use disorder at one of three locations: Merakey Parkside at 5000 Parkside, Merakey 5429 Germantown Avenue, or Merakey 1745 North 4th StreetNow Interest in starting methadone treatment for opioid use disorder at a partner location
    Sponsor University of Pennsylvania→Ashish P Thakrar, MD MS
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06877858
Lead sponsor
Ashish P Thakrar, MD MS
Responsible party
Ashish P Thakrar, MD MS (Assistant Professor of Medicine, University of Pennsylvania) — Sponsor-investigator
First posted
Mar 14, 2025
Start date
Sep 25, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Ashish P Thakrar, MD, MS
Contact
apthakrar@pennmedicine.upenn.edu
(215) 662-2250
Kyle Kampman, MD
Contact
kampman@pennmedicine.upenn.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion